Patents by Inventor Rony Seger

Rony Seger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy for the treatment of cancer
    Patent number: 11471504
    Abstract: An article of manufacture is disclosed which comprises: (i) a peptide agent which is capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus; and (ii) a MEK inhibitor. Uses thereof are also disclosed.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: October 18, 2022
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yardena Samuels, Rand Arafeh, Karen Flores, Rony Seger, Ehud Wainstein
  • INHIBITORS OF ERK NUCLEAR TRANSLOCATION
    Publication number: 20210292338
    Abstract: Described herein are compounds having Formula I or Formula II: wherein each dashed line independently represents a saturated or unsaturated bond; R1 and R?1 are aryl or heteroaryl as defined herein; and R2 and R?2 are as defined herein. Further described is a method of inhibiting nuclear translocation of ERK1/2 in a cell, by contacting the cell with a compound having Formula I or Formula II. The compounds may also be for use in treating a disease or disorder associated with nuclear translocation of ERK1/2.
    Type: Application
    Filed: June 3, 2021
    Publication date: September 23, 2021
    Applicants: Yeda Research and Development Co. Ltd., Universitat de Barcelona, Institució Catalana de Recerca I Estudis Avançats
    Inventors: Rony SEGER, Karen FLORES, Xavier BARRIL ALONSO, Carlos GALDEANO CANTADOR
  • COMBINATION THERAPY FOR THE TREATMENT OF CANCER
    Publication number: 20210154261
    Abstract: An article of manufacture is disclosed which comprises: (i) a peptide agent which is capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus; and (ii) a MEK inhibitor. Uses thereof are also disclosed.
    Type: Application
    Filed: July 24, 2018
    Publication date: May 27, 2021
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Yardena SAMUELS, Rand ARAFEH, Karen FLORES, Rony SEGER, Ehud WAINSTEIN
  • Use of inhibitory peptides for the treatment of inflammatory diseases
    Patent number: 10246488
    Abstract: An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.
    Type: Grant
    Filed: June 15, 2017
    Date of Patent: April 2, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Eldar Zehorai
  • ERK-derived peptides and uses thereof
    Patent number: 10240133
    Abstract: An isolated peptide being no longer than 20 amino acids comprising a sequence at least 95% homologous to the sequence GQLNHILGILGX1PX2QED (SEQ ID NO: 4), wherein X1 and X2 are any amino acid, the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus.
    Type: Grant
    Filed: April 27, 2017
    Date of Patent: March 26, 2019
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Alexander Plotnikov
  • Nuclear targeting sequences
    Patent number: 10000771
    Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: June 19, 2018
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Dana Chuderland
  • NUCLEAR TARGETING SEQUENCES
    Publication number: 20180066286
    Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.
    Type: Application
    Filed: November 1, 2017
    Publication date: March 8, 2018
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Rony SEGER, Dana CHUDERLAND
  • USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20170283457
    Abstract: An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.
    Type: Application
    Filed: June 15, 2017
    Publication date: October 5, 2017
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Rony SEGER, Eldar ZEHORAI
  • ERK-DERIVED PEPTIDES AND USES THEREOF
    Publication number: 20170233702
    Abstract: An isolated peptide being no longer than 20 amino acids comprising a sequence at least 95% homologous to the sequence GQLNHILGILGX1PX2QED (SEQ ID NO: 4), wherein X1 and X2 are any amino acid, the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus.
    Type: Application
    Filed: April 27, 2017
    Publication date: August 17, 2017
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Rony SEGER, Alexander PLOTNIKOV
  • Use of inhibitory peptides for the treatment of inflammatory diseases
    Patent number: 9714268
    Abstract: An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.
    Type: Grant
    Filed: April 24, 2014
    Date of Patent: July 25, 2017
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Eldar Zehorai
  • ERK-derived peptides and uses thereof
    Patent number: 9695402
    Abstract: An isolated peptide being no longer than 20 amino acids comprising a sequence at least 95% homologous to the sequence GQLNHILGILGX1PX2QED (SEQ ID NO: 4), wherein X1 and X2 are any amino acid, the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: July 4, 2017
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Alexander Plotnikov
  • ERK-DERIVED PEPTIDES AND USES THEREOF
    Publication number: 20160340655
    Abstract: An isolated peptide being no longer than 20 amino acids comprising a sequence at least 95% homologous to the sequence GQLNHILGILGX1PX2QED (SEQ ID NO: 4), wherein X1 and X2 are any amino acid, the peptide being capable of preventing extracellular signal-regulated kinase1/2 (ERK) translocation into the nucleus.
    Type: Application
    Filed: September 15, 2014
    Publication date: November 24, 2016
    Inventors: Rony SEGER, Alexander PLOTNIKOV
  • NUCLEAR TARGETING SEQUENCES
    Publication number: 20160222415
    Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.
    Type: Application
    Filed: April 13, 2016
    Publication date: August 4, 2016
    Applicant: Yeda Research and Development Co. Ltd.
    Inventors: Rony SEGER, Dana CHUDERLAND
  • Nuclear targeting sequences
    Patent number: 9315547
    Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: April 19, 2016
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Dana Chuderland
  • USE OF INHIBITORY PEPTIDES FOR THE TREATMENT OF INFLAMMATORY DISEASES
    Publication number: 20160052967
    Abstract: An isolated peptide is disclosed which comprises an amino acid sequence being at least 80% homologous to the sequence as set forth in SEQ ID NO: 1 (PERYQNLSPV), the isolated peptide comprising a nuclear targeting activity, the peptide being no longer than 20 amino acids.
    Type: Application
    Filed: April 24, 2014
    Publication date: February 25, 2016
    Inventors: Rony SEGER, Eldar ZEHORAI
  • NUCLEAR TARGETING SEQUENCES
    Publication number: 20140212438
    Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.
    Type: Application
    Filed: April 3, 2014
    Publication date: July 31, 2014
    Applicant: Yeda Research and Development Co., Ltd.
    Inventors: Rony SEGER, Dana Chuderland
  • Nuclear targeting sequences
    Patent number: 8748371
    Abstract: Isolated peptides comprising nuclear targeting activity or being capable of preventing endogenous nuclear targeting activity are disclosed. Polynucleotides encoding same, pharmaceutical compositions comprising same, as well as uses thereof are also disclosed.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: June 10, 2014
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Dana Chuderland
  • Variants of pigment epithelium derived factor and uses thereof
    Patent number: 8530416
    Abstract: The present invention provides anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising at least one altered phosphorylation site, polynucleotides encoding same and uses thereof. Particularly, the present invention provides variants of human PEDF comprising at least one amino acid substitution at serine residues (24), (114), and (227). The PEDF variants are potent anti-angiogenic factors, and thus useful in treating diseases or disorders associated with neovascularization.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: September 10, 2013
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Rony Seger, Galia Maik-Rachline
  • VARIANTS OF PIGMENT EPITHELIUM DERIVED FACTOR AND USES THEREOF
    Publication number: 20120184481
    Abstract: The present invention provides anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising at least one altered phosphorylation site, polynucleotides encoding same and uses thereof. Particularly, the present invention provides variants of human PEDF comprising at least one amino acid substitution at serine residues (24), (114), and (227). The PEDF variants are potent anti-angiogenic factors, and thus useful in treating diseases or disorders associated with neovascularization.
    Type: Application
    Filed: April 3, 2012
    Publication date: July 19, 2012
    Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. at the Weizmann Institute of Science
    Inventors: Rony Seger, Galia Maik-Rachline
  • Variants of pigment epithelium derived factor and uses thereof
    Patent number: 8173591
    Abstract: The present invention provides anti-angiogenic variants of pigment epithelium derived factor (PEDF) comprising at least one altered phosphorylation site, polynucleotides encoding same and uses thereof. Particularly, the present invention provides variants of human PEDF comprising at least one amino acid substitution at serine residues (24), (114), and (227). The PEDF variants are potent anti-angiogenic factors, and thus useful in treating diseases or disorders associated with neovascularization.
    Type: Grant
    Filed: November 16, 2004
    Date of Patent: May 8, 2012
    Assignee: Yeda Research and Development Co.
    Inventors: Rony Seger, Galia Maik-Rachline